MSCO | QNA

Thank your for your time!

Q1. According to the video, is there a justification for running a non-inferiority trial in the first place?

A: Yes, for trastuzumab <24 m with benefit of cheaper, more convenient and less cardiotoxic. 0%

B: Yes, for trastuzumab >24 m with benefit of cheaper, more convenient and less cardiotoxic. 0%

C: Yes, for trastuzumab <12 m with benefit of cheaper, more convenient and less cardiotoxic. 0%

D: Yes, for trastuzumab >12 m with benefit of cheaper, more convenient and less cardiotoxic. 0%

Referring to speaker slides at time: 11:32 talking about when and how for non-inferiority trials.

Q2. What are the updated results for IDFS at 7 years in small tumors data of APT trial?

A: Overall IDFS is 98.7% (95%CI = 97.6, 99.8) 0%

B: Overall IDFS is 93.3% (95%CI = 90.4, 96.2) 0%

C: Overall IDFS is 90.1% (95%CI = 90.4, 96.2) 0%

D: Overall IDFS is 87.6% ( 95%CI = 90.4, 96.2) 0%

Referring to speaker slides at time: 19:08 talking about the updated results for small tumors data of APT trial on the right hand side of slide.

Q3. Which one of the following is NOT the conclusions about decreasing the burden according to the speaker?

A: With more efficient anti-HER2 therapies, the time has come to cautiously explore de-escalation of chemotherapy, ensuring toxicity is addressed but efficacy is not compromised. 0%

B: The neoadjuvant setting is the safest route to de-escalation due to its intermediate surrogate endpoint (pCR). 0%

C: DecreSCendo and COMPASS trials have the potential to establish an anthracycline-free neoadjuvant/adjuvant strategy. 0%

D: Combination of selected baseline biomarkers with a response-adapted de-escalation strategy could not lead to complete omission of chemotherapy. 0%

Referring to conclusion I & II slides at time: 37:30 - 38:20 and PHERGain Trial.

(Ref: DOI: 10.1200/JCO.2020.38.15_suppl.503 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 503-503.)

Q4. For the patient casesharing about neoadjuvant therapy and surgery, what is the residual invasive tumour size?

A: 4 mm 0%

B: 6 mm 0%

C: 8 mm 0%

D: 10 mm 0%

Referring to the patient case sharing slides at time: 41:47. After treating the patient using Paclitaxel weekly x 12 (80mg/m2/wk) with trastuzumab, the residual invasive tumor is 6mm. (ER+PR+HER2+++)

Q5. What is the absolute benefit of small tumors at surgery according to KATHERINE trial subgroup analysis 3 years IDFS rate % using T-DM1?

A: 88.3% 0%

B: 88.3% 0%

C: 83.6% 0%

D: 63.8% 0%

Referring to slide at 42:14. The speaker emphasized the benefit with the red circle about the data %.